NASDAQ: QNRXQuoin Pharmaceuticals Ltd Stock
$0.71-0.01 (-1.39%)
Updated Apr 19, 2024
QNRX Price
$0.71
Fair Value Price
$4,821.46
Market Cap
$2.62M
52 Week Low
$0.69
52 Week High
$12.00
P/E
N/A
P/B
0.46x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$8.69M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.15
Operating Cash Flow
-$8M
Beta
1.55
Next Earnings
May 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
QNRX Overview
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how QNRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
QNRX ($0.71) is undervalued by 99.99% relative to our estimate of its Fair Value price of $4,821.46 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
QNRX ($0.71) is significantly undervalued by 99.99% relative to our estimate of its Fair Value price of $4,821.46 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
QNRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more QNRX due diligence checks available for Premium users.
Be the first to know about important QNRX news, forecast changes, insider trades & much more!
QNRX News
Valuation
QNRX fair value
Fair Value of QNRX stock based on Discounted Cash Flow (DCF)
Price
$0.71
Fair Value
$4,821.46
Undervalued by
99.99%
QNRX ($0.71) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
QNRX ($0.71) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
QNRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
15.81x
Market
40.51x
QNRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.46x
Industry
5.74x
QNRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
QNRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.0M
Profit Margin
0%
QNRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$12.2M
Liabilities
$6.5M
Debt to equity
1.15
QNRX's short-term assets ($11.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
QNRX's short-term assets ($11.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
QNRX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
QNRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.2M
Investing
$2.6M
Financing
-$182.6k
QNRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
QNRX vs Biotech Stocks
Quoin Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.